Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, in…

Read MoreMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)

Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance

Pfizer Inc. (NYSE:PFE) today announced that it has amended its supply agreement with the U.S. government for Paxlovid, the first oral antiviral pill approved by the U.S. Food and Drug Administration (FDA) and is updating its Full-Year 2023 Guidance. Paxlovid…

Read MorePfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance

U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC). The approved recommended dose…

Read MoreU.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)

Heidelberg Engineering Announces FDA Clearance for All-in-One ANTERION Platform

Heidelberg Engineering, a global leader in ophthalmic imaging and healthcare data solutions, announces FDA clearance of its innovative all-in-one ANTERION® platform, designed to transform anterior segment diagnostics and streamline practice workflow. “Building upon our previous CE-marking, we are thrilled that the ANTERION…

Read MoreHeidelberg Engineering Announces FDA Clearance for All-in-One ANTERION Platform

Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023

Novocure (NASDAQ: NVCR) today announced its participation in the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 – 24 in Madrid. Novocure will present three new posters on Tumor Treating Fields (TTFields) therapy, including an analysis of…

Read MoreNovocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023

GE HealthCare Announces Study Results Demonstrating Portrait Mobile Continuous Monitoring Solution Performance with Patients and Care Teams in the Ward

GE HealthCare (Nasdaq: GEHC) today announced new data from a pilot study conducted with Cleveland Clinic evaluating the Portrait Mobile wireless and wearable monitoring solution. The results demonstrate that continuous patient monitoring with Portrait Mobile resulted in alarm data suitable…

Read MoreGE HealthCare Announces Study Results Demonstrating Portrait Mobile Continuous Monitoring Solution Performance with Patients and Care Teams in the Ward

New Phase 1 Dose Escalation Cohorts Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic Effects at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today presented new pharmacodynamic data from the ongoing Phase 1 dose escalation portion of its Phase 1/2 clinical trial of AU-007, the…

Read MoreNew Phase 1 Dose Escalation Cohorts Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic Effects at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

MUST Connect 2023 Singapore highlighted the cutting-edge innovations of Korean life science startups

MUST Connect 2023 Singapore, a roadshow that helps Korean life science startups expand overseas by connecting them with global pharmaceutical companies and investors, was held on Oct. 11 (Wed.) and 12 (Thu.) at Singapore Science Park. Twelve Korean startups showcased…

Read MoreMUST Connect 2023 Singapore highlighted the cutting-edge innovations of Korean life science startups

Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Avistone Biotechnology Co., Ltd (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced results from its China and US IND enabling nonclinical studies for ANS014004 (“ANS01”), a novel small-molecule type II c-Met tyrosine kinase…

Read MoreAvistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline

AbbVie (NYSE: ABBV) announced today that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinson’s Disease (PD). Mitokinin’s lead compound, a selective PINK1 activator, is…

Read MoreAbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline

Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer

 Novartis will present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, highlighting latest developments from across its oncology portfolio and addressing unmet needs of patients diagnosed with some of the…

Read MoreNovartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer

Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of six antibodies specific to dupilumab (Dupixent) and the addition…

Read MoreBio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development